[1] Kim SM, Ryu V, Miyashita S, et al. Thyrotropin, hyperthyroidism, and bone mass. J Clin Endocrinol Metab, 2021, 106(12): e4809-e4821. [2] Zhao P, Hu Z, Ma W, et al. Quercetin alleviates hyperthyroidism-induced liver damage via Nrf2 signaling pathway. Biofactors, 2020, 46(4): 608-619. [3] Zhang W, Wang X, Li P, et al. Evaluating hyperthyroidism-induced liver injury based on in situ fluorescence imaging of glutathione and phosphate via Nano-MOFs sensor. Anal Chem, 2020, 92(13): 8952-8958. [4] Li X, Jin S, Fan Y, et al. Association of HLA-C*03: 02 with methimazole-induced liver injury in Graves' disease patients. Biomed Pharmacother, 2019, 117: 109095. [5] Piantanida E, Ippolito S, Gallo D, et al. The interplay between thyroid and liver: implications for clinical practice. J Endocrinol Invest, 2020, 43(7): 885-899. [6] Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid, 2016, 26(10): 1343-1421. [7] 陆再英, 终南山. 内科学. 7版. 北京: 人民卫生出版社, 2008: 717. [8] 盛秋菊, 丁洋, 张翀, 等. HT合并肝损伤患者的临床特点分析. 中华肝脏病杂志, 2021, 29(10): 967-971. [9] Yang Q, Liu W, Sun D, et al. Yinning tablet, a hospitalized preparation of Chinese herbal formula for hyperthyroidism, ameliorates thyroid hormone-induced liver injury in rats: Regulation of mitochondria-mediated apoptotic signals. J Ethnopharmacol, 2020, 252: 112602. [10] Zhang Q, Liu S, Guan Y, et al. RNASET2, GPR174, and PTPN22 gene polymorphisms are related to the risk of liver damage associated with the hyperthyroidism in patients with Graves' disease. J Clin Lab Anal, 2018, 32(2): e22258. [11] Sisti E, Coco B, Menconi F, et al. Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves' orbitopathy. Thyroid, 2015, 25(7): 846-850. [12] Opoku-Akyeampong NAAS, Agyei-Nkansah A, Yorke E. Liver dysfunction associated with hyperthyroidism: lessons from 2 case reports. Clin Case Rep, 2021, 9(6): e04067. [13] Azizi F, Abdi H, Cheraghi L, et al. Treatment of subclinical hyperthyroidism in the elderly: comparison of radioiodine and long-term methimazole treatment. Thyroid, 2020, 31(4): 545-551. [14] Yavuz DG, Apaydin T, Elbasan O. Preoperative plasmapheresis experience in Graves' disease patients with anti-thyroid drug-induced hepatotoxicity. Transfus Apher Sci, 2020, 59(5): 102826. [15] Yu W, Wu N, Li L, et al. Side effects of PTU and MMI in the treatment of hyperthyroidism: a systematic review and meta-analysis. Endocr Pract, 2020, 26(2): 207-217. [16] Kawkgi OME, Ross DS, Stan MN. Comparison of long-term antithyroid drugs versus radioactive iodine or surgery for Graves' disease: A review of the literature. Clin Endocrinol, 2021, 95(1): 3-12. [17] Apaydn T, Yavuz DG. Preoperative plasmapheresis in patients with Graves' disease intolerant to antithyroid drugs. Ther Apher Dial, 2021, 25(6): 877-883. [18] Vrachnis N, Tsonis O, Vrachnis D, et al. The effect of thyrotropin-releasing hormone and antithyroiddrugs on fetal thyroid function. Children, 2021, 8(6): 454. [19] Piantanida E, Ippolito S, Gallo D, et al. The interplay between thyroid and liver: implications for clinical practice. J Endocrinol Invest, 2020, 43(8): 885-899. [20] Weissman S, Rajaratnam NG, Qureshi N, et al. Drug-induced liver tnjury: a unique presentation of single-dose administration of propylthiouracil. J Investig Med High Impact Case Rep, 2020, 8: 232470962095132. |